Urinary Tract Infections – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Urinary Tract Infections – Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Tract Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections
- The report reviews pipeline therapeutics for Urinary Tract Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Urinary Tract Infections therapeutics and enlists all their major and minor projects
- The report assesses Urinary Tract Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Urinary Tract Infections
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AbbVie IncAdicet Bio Inc
Advanz Pharma Corp Ltd
Allecra Therapeutics GmbH
Antabio SAS
Beijing FuKangren Bio-pharm Tech Co Ltd
Bioharmony Therapeutics Inc
BioNTech SE
CAMP Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Cipla USA Inc
Curza Global LLC
Daiichi Sankyo Co Ltd
Edenbridge Pharmaceuticals LLC
Entasis Therapeutics Holdings Inc
Enteris BioPharma Inc
Everest Medicines Ltd
Evopoint Bioscience Co Ltd
Evotec SE
Fimbrion Therapeutics Inc
Forge Therapeutics Inc
Gamaleya Federal Research Center of Epidemiology and Microbiology
Genentech USA Inc
Greenpine Pharmaceutical Group Co Ltd
GSK plc
Helperby Therapeutics Group Ltd
Hennepin Life Sciences LLC
Immuron Ltd
Infex Therapeutics Ltd
Inmunotek SL
Iterum Therapeutics Plc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu ProteLight Pharmaceutical & Biotechnology Co Ltd
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Jiangsu Yahong Meditech Co Ltd
Kyung Dong Co Ltd
Lakewood-Amedex Inc
Locus Biosciences Inc
LUCA Biologics Inc
lysentech
Madam Therapeutics BV
Meiji Seika Pharma Co Ltd
Melinta Therapeutics LLC
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Miyarisan Pharmaceutical Company Ltd
Nabriva Therapeutics Plc
Nanjing Yoko Pharmaceutical Co Ltd
Northern Antibiotics Oy
Nosopharm SAS
NRX Pharmaceuticals Inc
Octagon Therapeutics Inc
Omnix Medical Ltd
Organon & Co
Osel Inc
Paldara Inc
Paratek Pharmaceuticals Inc
Pedanius Therapeutics Ltd
Pfizer Inc
PHAXIAM Therapeutics SA
PHIOGEN INC
Prokaryotics Inc
Pylum Biosciences Inc
Qilu Pharmaceutical Co Ltd
Qpex Biopharma Inc
Recce Pharmaceuticals Ltd
Red Leaf Medical Inc.
Revagenix Inc
SciClone Pharmaceuticals Holdings Ltd
Seed Health Inc
Sequoia Vaccines Inc
Shanghai New Asia Pharmaceutical Co Ltd
Shionogi & Co Ltd
Spero Therapeutics Inc
Sumitomo Pharma Co Ltd
Summit Therapeutics Inc
SuperTrans Medical Ltd
Syntiron LLC
TCM Biotech International Corp
TechnoPhage SA
Telum Therapeutics SL
University of Queensland
University of Texas at Dallas
Uqora Inc
UTILITY Therapeutics Ltd
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
Zai Lab Ltd
Zensun (Shanghai) Sci & Tech Co Ltd